| |
Fig. 2. FoxD5 is required for the normal expression of NE genes. (A) Myc-tagged FoxD5 (foxD5-MT) is highly expressed in both the cytoplasm and nucleus (arrowheads); this expression is greatly reduced in the presence of foxD5-MOs (foxMOs). Myc-tagged N-terminal deleted FoxD5 (δN-foxD5) is strongly expressed even in the presence of foxMOs. (B) Control MO (cMO) does not alter the expression of sox2 on the injected side () of the embryo (st14, dorsal view, anterior is down). (C) Co-injection of δNfoxD5 mRNA prevents the foxMOs reduction of sox2 expression (cf. E) on the injected side () of the embryo (st15, same view as in B). (D) The percentage of embryos exhibiting the phenotypes shown in E (reduced expression above x-axis; expanded expression below x-axis) after injection of foxD5-MOs (analyzed at four different stages), cMO (analyzed at st14) or foxD5-MOs + δNfoxD5 mRNA (analyzed at st14). These data indicate that the effects of foxD5-MOs are specific and can be rescued in a high percentage of cases by δNfoxD5. Sample sizes are indicated above each bar. (E) Arrows denote patches of reduced gene expression at the site of foxD5-MOs injection for each NE gene at gastrulation (st10.5–12) and neural plate (st13–15) stages. For zic1 and zic3, foxD5-MOs expand their expression domains at neural plate stages (lines denote width of neural plate on injected sides). For gem, sox2, zic2, zic3, Xiro1 and Xiro2: dorsal views with anterior to the bottom; for sox3, anterior view with dorsal to the top; for sox11, soxD, and zic1: gastrula stages are dorsal views (as for gem) and neural plate stages are anterior views (as for sox3); for Xiro3: st10.5 is vegetal view with dorsal to the top and st13 is dorsal view (as for Xiro1, 2). |
